Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors

World Journal of Gastroenterology

Volumn 19, Issue 30, 2013, Pages 4887-4896

  Matsumura, Hiroshi ^a   Nirei, Kazushige ^a   Nakamura, Hitomi ^a   Higuchi, Teruhisa ^a   Arakawa, Yasuo ^a   Ogawa, Masahiro ^a   Tanaka, Naohide ^a   Moriyama, Mitsuhiko ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic liver disease; Hepatocellular carcinoma; Histopathology of liver biopsy; Irregular regeneration of hepatocytes; Liver fibrosis; Type

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; CANFERON; HEPATITIS C ANTIBODY; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CELL INFILTRATION; CHOLESTASIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; INFLAMMATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NECROSIS; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SCORING SYSTEM; THROMBOCYTE COUNT;

EID: 84881521733     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i30.4887     Document Type: Article

References (36)

1. Matsumura H, Moriyama M, Goto I, Tanaka N, Okubo H, Arakawa Y. Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C--a study of 527 patients at one establishment. J Viral Hepat 2000; 7: 268-275 [PMID: 10886535 DOI: 10.1046/ j.1365-2893.2000.00235. x]
2. Leone N, Rizzetto M. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol 2005; 51: 31-46 [PMID: 15756144]
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832 [PMID: 9121257 DOI: 10.1016/ S0140-6736(96)07642-8]
4. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-938 [PMID: 9672166 DOI: 10.1016/S0168-8278(98)80339-5]
5. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-524 [PMID: 10744587]
6. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-181 [PMID: 10428733]
7. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50 [PMID: 15508101 DOI: 10.1053/ j. gastro.2004.09.014]
8. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127: S17-S26 [PMID: 15508082 DOI: 10.1053/j. gastro.2004.09.012]
9. Uchida T. Small hepatocellular carcinoma: its relationship to multistep hepatocarcinogenesis. Pathol Int 1995; 45: 175-184 [PMID: 7787987 DOI: 10.1111/j.1440-1827.1995. tb03440. x]
10. Shibata M, Morizane T, Uchida T, Yamagami T, Onozuka Y, Nakano M, Mitamura K, Ueno Y. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998; 351: 1773-1777 [PMID: 9635950 DOI: 10.1016/ S0140-6736(97)08002-1]
11. Ueno Y, Moriyama M, Uchida T, Arakawa Y. Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease. Hepatology 2001; 33: 357-362 [PMID: 11172337 DOI: 10.1053/jhep.2001.21902]
12. Moriyama M, Matsumura H, Oshiro S, Nakamura H, Arakawa Y, Nirei K, Aoki H, Yamagami H, Kaneko M, Tanaka N, Arakawa Y. Interferon therapy improves the irregular regeneration of hepatocytes in liver in patients with C-viral chronic hepatitis and liver cirrhosis. Intervirology 2007; 50: 138-149 [PMID: 17191016 DOI: 10.1159/000098240]
13. Taguchi K, Aishima S, Matsuura S, Terashi T, Nishiyama K, Shirabe K, Shimada M, Maehara Y, Tsuneyoshi M. Significance of the relationship between irregular regeneration and two hepatocarcinogenic pathways: "de novo" and so-called "dysplastic nodule-hepatocellular carcinoma" sequence. J Surg Oncol 2005; 92: 100-103 [PMID: 16231367 DOI: 10.1002/ jso.20293]
14. Miyakawa H, Fujikawa H, Kikuchi K, Kitazawa E, Kawashima Y. Irregular regeneration of hepatocytes and development of hepatocellular carcinoma in primary biliary cirrhosis. Am J Gastroenterol 2002; 97: 488 [PMID: 11866295 DOI: 10.1111/j.1572-0241.2002.05503. x]
15. Moriyama M, Mikuni M, Matsumura H, Nakamura H, Oshiro S, Aoki H, Shimizu T, Yamagami H, Shioda A, Kaneko M, Tanaka N, Arakawa Y. SEN virus infection influences the pathological findings in liver but does not affect the incidence of hepatocellular carcinoma in patients with chronic hepatitis C and liver cirrhosis. Liver Int 2005; 25: 226-235 [PMID: 15780043 DOI: 10.1111/j.1478-3231.2005.01076. x]
16. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520 [PMID: 8188183]
17. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435 [PMID: 7308988 DOI: 10.1002/ hep.1840010511]
18. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699 [PMID: 7560864]
19. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16 [PMID: 11296695 DOI: 10.1055/s-2001-12925]
20. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419 [PMID: 10348825]
21. Yamasaki T, Terai S, Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med 2011; 365: 576-578 [PMID: 21830988 DOI: 10.1056/NEJMc1105726]
22. Choi J. Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: pathogenic interactions and therapeutic considerations. Free Radic Biol Med 2012; 52: 1135-1150 [PMID: 22306508]
23. Ivanov AV, Bartosch B, Smirnova OA, Isaguliants MG, Kochetkov SN. HCV and oxidative stress in the liver. Viruses 2013; 5: 439-469 [PMID: 23358390 DOI: 10.3390/v5020439]
24. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055 [PMID: 7564784 DOI: 10.1016/S0140-6736(95)91739-X]
25. Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593-602 [PMID: 11394661 DOI: 10.1016/S0168-8278(01)00005-8]
26. Kumar M, Kumar R, Hissar SS, Saraswat MK, Sharma BC, Sakhuja P, Sarin SK. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a casecontrol study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol 2007; 22: 1104-1111 [PMID: 17559381 DOI: 10.1111/j.1440-1746.2007.04908. x]
27. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-1067 [PMID: 9734402 DOI: 10.1038/2053]
28. International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-664 [PMID: 19177576 DOI: 10.1002/hep.22709]
29. Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 2000; 33: 282-289 [PMID: 10952246 DOI: 10.1016/ S0168-8278(00)80369-4]
30. Miyaaki H, Fujimoto M, Kurogi M, Nakashima O, Eguchi K, Kojiro M. Pathomorphological study on small nodular lesions in hepatitis C virus-related cirrhosis. Oncol Rep 2005; 14: 1469-1474 [PMID: 16273240]
31. Tokushige K, Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Shiratori K. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol 2010; 45: 960-967 [PMID: 20376504 DOI: 10.1007/s00535-010-0237-1]
32. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832 [PMID: 20432259 DOI: 10.1002/hep.23594]
33. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46 Suppl 1: 63-69 [PMID: 20844903 DOI: 10.1007/ s00535-010-0311-8]
34. Migita K, Watanabe Y, Jiuchi Y, Nakamura Y, Saito A, Yagura M, Ohta H, Shimada M, Mita E, Hijioka T, Yamashita H, Takezaki E, Muro T, Sakai H, Nakamuta M, Abiru S, Komori A, Ito M, Yatsuhashi H, Nakamura M, Ishibashi H. Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). Liver Int 2012; 32: 837-844 [PMID: 22221966 DOI: 10.1111/ j.1478-3231.2011.02734. x]
35. Jiang Z, Jhunjhunwala S, Liu J, Haverty PM, Kennemer MI, Guan Y, Lee W, Carnevali P, Stinson J, Johnson S, Diao J, Yeung S, Jubb A, Ye W, Wu TD, Kapadia SB, de Sauvage FJ, Gentleman RC, Stern HM, Seshagiri S, Pant KP, Modrusan Z, Ballinger DG, Zhang Z. The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res 2012; 22: 593-601 [PMID: 22267523 DOI: 10.1101/gr.133926.111]
36. Tan YJ. Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J Gastroenterol 2011; 17: 4853-4857 [PMID: 22171125 DOI: 10.3748/wjg. v17. i44.4853]